Harald Reinhart - 03 Mar 2023 Form 4 Insider Report for Zai Lab Ltd (ZLAB)

Role
President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases
Signature
/s/ Bruce Blefeld, Attorney-in-Fact
Issuer symbol
ZLAB
Transactions as of
03 Mar 2023
Net transactions value
-$424,760
Form type
4
Filing time
07 Mar 2023, 15:05:19 UTC
Previous filing
03 Jan 2023
Next filing
03 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZLAB American Depositary Shares Options Exercise $34,440 +11,480 +61% $3.00* 30,438 03 Mar 2023 Direct F1, F2
transaction ZLAB American Depositary Shares Sale $459,200 -11,480 -38% $40.00 18,958 03 Mar 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZLAB Stock Options (Right to Buy) Options Exercise $0 -11,480 -100% $0.000000* 0 03 Mar 2023 American Depositary Shares 11,480 $3.00 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
F2 The reported transaction was effected pursuant to a sale plan adopted by the Reporting Person, dated 08/23/2022, that expires on 06/30/2023 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
F3 The options vest in equal installments over four years beginning on 5/12/2018, the first anniversary of the date of grant.

Remarks:

President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases